Tesamorelin + Ipamorelin + CJC-1295 3mg / 3mg / 3mg blend

Tesamorelin + Ipamorelin + CJC-1295 3mg / 3mg / 3mg blend is a multi-peptide lyophilized research preparation supplied exclusively for scientific investigation and controlled laboratory experimentation.

For research use only — not for human or veterinary use.

 

Product Overview

Tesamorelin + Ipamorelin + CJC-1295 3mg / 3mg / 3mg blend is a multi-peptide research preparation combining three distinct peptide compounds within a single lyophilized research vial.

The formulation contains 3 mg Tesamorelin, 3 mg Ipamorelin and 3 mg CJC-1295, providing a total nominal peptide content of 9 mg.

Each component represents a distinct area of experimental peptide research. Tesamorelin and CJC-1295 are investigated within controlled laboratory models involving growth hormone-releasing factor-associated peptide signalling, while Ipamorelin is studied within experimental growth hormone secretagogue receptor and peptide signalling research.

Independent third-party laboratory analysis of this production batch measured assay contents of 3.23 mg Tesamorelin, 3.07 mg Ipamorelin and 3.36 mg CJC-1295.

Identity was independently evaluated through retention time analysis and mass spectrometry, with molecular ion masses identified at 5135 Da for Tesamorelin, 711 Da for Ipamorelin and 3367 Da for CJC-1295.

Microbiological testing reported 0 CFU/g for both total aerobic microbial count and total yeast and mold count, while bacterial endotoxin analysis returned a result of 0.033 EU/mg.

Comprehensive elemental impurity screening additionally reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm.

With all three peptide components independently characterised for assay content and molecular identity, this blend provides researchers with transparent batch-specific analytical documentation suitable for advanced peptide investigations and controlled in vitro laboratory studies.

 

Peptide Overview

This 9 mg research blend combines three peptide research compounds: Tesamorelin, Ipamorelin and CJC-1295.

Tesamorelin is a synthetic peptide research compound investigated within experimental models involving growth hormone-releasing factor-associated molecular signalling and peptide receptor biology.

Ipamorelin is a synthetic peptide research compound investigated within controlled laboratory models involving growth hormone secretagogue receptor-associated signalling and peptide-receptor interactions.

CJC-1295 is a peptide research compound investigated within experimental models involving growth hormone-releasing factor-associated signalling, peptide receptor interactions and intracellular molecular communication.

Combining Tesamorelin, Ipamorelin and CJC-1295 within a single research preparation provides investigators with a multi-component material for controlled comparative and combined peptide research.

Each component within this production batch was independently analysed for assay content and retention time identity, with additional molecular ion mass identification performed through mass spectrometry.

 

Historical Background and Scientific Context

Advances in peptide engineering have enabled researchers to develop increasingly sophisticated peptide compounds for investigating receptor signalling, molecular communication and intracellular regulatory mechanisms.

Growth hormone-releasing factor and growth hormone secretagogue peptides represent established areas of experimental peptide research, providing laboratory models for investigating distinct receptor-mediated signalling pathways.

Tesamorelin, Ipamorelin and CJC-1295 represent structurally distinct research peptides that can be characterised individually within a combined experimental preparation.

Modern analytical technologies including chromatographic analysis and mass spectrometry have significantly improved the ability to verify individual peptide content and molecular identity within multi-component research preparations.

Microbiological analysis, bacterial endotoxin testing and elemental impurity screening provide additional batch-specific analytical information for controlled laboratory research materials.

 

Mechanistic Focus in Research

Within controlled laboratory environments, Tesamorelin, Ipamorelin and CJC-1295 may be investigated in relation to peptide receptor signalling and intracellular molecular communication systems.

Research investigations frequently explore:

• Multi-peptide interaction research
• Growth hormone-releasing factor-associated signalling
• Growth hormone secretagogue receptor research
• Peptide receptor signalling pathways
• Receptor-mediated intracellular communication
• Cellular regulatory mechanisms
• Biochemical pathway analysis
• Comparative peptide investigations
• Controlled in vitro multi-peptide studies

These experimental models allow researchers to investigate multiple peptide-related molecular systems while maintaining carefully controlled laboratory conditions.

 

Analytical Verification (COA)

Each batch of Tesamorelin + Ipamorelin + CJC-1295 3mg / 3mg / 3mg blend supplied by Grail Formula undergoes comprehensive independent third-party laboratory analysis to characterise the individual peptide components and important laboratory quality parameters.

Analytical testing for this batch was performed by Liquilabs s.r.o. Czechia using chromatographic, microbiological and mass spectrometry techniques.

Batch: GF-TEIPCJ-B241

• Tesamorelin Assay Content: 3.23 mg
• Tesamorelin Identification by Retention Time: 0.997
• Tesamorelin Molecular Ion Mass: 5135 Da
• Ipamorelin Assay Content: 3.07 mg
• Ipamorelin Identification by Retention Time: 0.994
• Ipamorelin Molecular Ion Mass: 711 Da
• CJC-1295 Assay Content: 3.36 mg
• CJC-1295 Identification by Retention Time: 0.996
• CJC-1295 Molecular Ion Mass: 3367 Da
• Bacterial Endotoxins: 0.033 EU/mg
• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

Independent peptide screening measured assay contents of 3.23 mg for Tesamorelin, 3.07 mg for Ipamorelin and 3.36 mg for CJC-1295, with a reported analytical uncertainty of ±0.02 mg for each component.

Retention time analysis returned 0.997 for Tesamorelin, 0.994 for Ipamorelin and 0.996 for CJC-1295.

Mass spectrometry identified molecular ion masses of 5135 Da for Tesamorelin, 711 Da for Ipamorelin and 3367 Da for CJC-1295.

Bacterial endotoxin testing returned a result of 0.033 EU/mg, within the laboratory’s reported acceptable range of 0–0.5 EU/mg.

Microbiological testing reported 0 CFU/g for total aerobic microbial count and 0 CFU/g for total yeast and mold count, within the laboratory’s reported acceptable ranges of 0–1000 CFU/g and 0–100 CFU/g respectively.

Independent elemental impurity analysis reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm, with all reported results within the laboratory’s stated acceptable ranges.

These analytical procedures provide independent batch-specific characterisation of all three peptide components together with microbiological, bacterial endotoxin and elemental impurity testing.

 

Research Applications

Within controlled laboratory environments, Tesamorelin + Ipamorelin + CJC-1295 3mg / 3mg / 3mg blend may be utilised in experimental models designed to investigate multi-peptide biology, receptor signalling and molecular regulatory mechanisms.

Examples of research applications include:

• Tesamorelin peptide research
• Ipamorelin peptide research
• CJC-1295 peptide research
• Multi-peptide interaction investigations
• Growth hormone-releasing factor-associated research
• Growth hormone secretagogue receptor research
• Peptide-mediated signalling studies
• Comparative peptide investigations
• Controlled in vitro multi-peptide studies

These applications are intended exclusively for scientific and laboratory investigation.

 

Grail Formula Quality

Every Grail Formula research compound is supported by comprehensive independent analytical verification and transparent batch-specific laboratory documentation.

For this multi-peptide production batch, independent laboratory testing included:

• Individual assay determination for all three peptide components
• Individual retention time identity verification
• Individual molecular ion mass identification
• Bacterial endotoxin analysis
• Total aerobic microbial count
• Total yeast and mold count
• Comprehensive elemental impurity screening
• Complete batch-specific traceability

Independent analysis of each peptide component provides researchers with detailed analytical information relating directly to the tested production batch rather than relying solely on the nominal formulation.

This approach supports analytical transparency, batch traceability and consistency across Grail Formula research compounds.

 

When You Choose Grail Formula

When selecting Grail Formula, researchers receive independently analysed research compounds supported by detailed Certificates of Analysis and transparent batch-specific laboratory documentation.

For Tesamorelin + Ipamorelin + CJC-1295 3mg / 3mg / 3mg blend batch GF-TEIPCJ-B241, independent analysis was performed by Liquilabs s.r.o. Czechia and the Certificate of Analysis was published on 20 September 2026.

All three peptide components were independently evaluated for assay content, retention time identity and molecular ion mass.

The analytical programme additionally included bacterial endotoxin testing, microbiological analysis and comprehensive elemental impurity screening.

This multi-method analytical approach provides researchers with extensive independent information regarding the individual components within the tested multi-peptide research preparation.

 

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.